procedures, and the use of new radio-and chemotherapeutic protocols 3 . This underscores a desperate need for new strategies in prevention, early detection, and treatment of this deadly disease. Tobacco use represents the major risk factor and is responsible for 71% of global lung cancer deaths 4 . Tobacco smoke is extremely complex, consisting of thousands of compounds, and over 60 carcinogens 5 . Several carcinogens, in particular, thought to be responsible for lung cancer development and progression include the polycyclic aromatic hydrocarbons and the nicotine-derived nitrosamines, N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), among others. The metabolites of these compounds cause mutations in vital genes such as Rb, p53, and KRAS 6 . However, it was recently shown that expression of oncogenic KRAS and knockdown of the tumor suppressor protein p53 were insufficient to confer a full malignant phenotype in bronchial epithelial cells, suggesting that the role these genes and their products play in lung cancer development may have been overemphasized 7 . This, along with emerging data suggesting an important role of the microenvironment in the etiology of many cancers, leads us to believe that other factors are involved.
We have focused our attention on nicotine, a major plant alkaloid in tobacco. Historically, nicotine was thought to only mediate smoking dependence and addiction by working through reward centers in the brain to cause a release of dopamine and a general sense of euphoria 8 . More recent data, however, reveal that, even though nicotine may be unable to initiate oncogenic transformation, it promotes cancer cell proliferation in vitro and may stimulate tumor progression [9] [10] [11] . Nicotine mediates its effects through nicotinic acetylcholine receptors (nAChRs) by mimicking acetylcholine, the endogenous ligand for these receptors 12 . NAChRs comprise a family of multimeric cation channel proteins that act as central regulators of a vital network of excitatory and inhibitory neurotransmitters that governs the function of all organs and cells in the mammalian organism. They are located in the plasma membrane and can exist as homo-or heteropentamers. Previously thought to exist only in the nervous system and neuromuscular junctions, they are now recognized as being universally expressed in mammalian cells, and in many cancers 13 . Upon ligand binding in the alpha subunit, the receptors undergo conformational changes that open the channel, allowing cations to rush down their concentration gradient, resulting in depolarization of the plasma membrane and activation of intracellular signal transduction pathways 14 .
The link between nAChRs and lung cancer was recently strengthened by studies identifying a common variant in the nAChR gene cluster on chromosome 15q25 with a predisposition to lung cancer 15 . This locus was found to account for 14% (attributable risk) of lung cancer cases. In tumor cells, activation of nAChR signaling stimulates cell proliferation, tumor progression, and metastasis through induction of the synthesis and release of growth, angiogenic, apoptotic, and metastatic factors 11 . However, both tumor cells and host cells of the tumor microenvironment express several of these receptors and the true contribution of distinct nAChRs in lung cancer remains unclear. Furthermore, studies evaluating these receptors have relied on chemical inhibitors, which are notorious for their off-target effects. Thus, the true role of distinct nAChRs in lung cancer remains incompletely understood.
Here, we evaluate the relative contribution of α7 and α4 nAChRs in lung cancer using Lewis Lung Carcinoma cells silenced for these receptors using shRNA technology. Our data suggest that although these receptors play distinct roles in several biological processes in tumor cells tested in vitro, with a predominant role for α4 nAChRs, targeting them individually did not lead to significant beneficial effects for the host in a rodent xenograft model. However, in experiments performed in genetically engineered animals to test the role of host cell α7 nAChRs, we observed larger tumor growth compared to wildtype animals. These studies underscore the need to carefully define the relative contributions of these receptors, in both host and tumor cells, prior to the development of interventions for treatment in humans. Silencing of α4 and α7 nAChRs with shRNA LLC cells (2.3x10 7 cells/mL) were permanently transfected with 160 µg of control, α4 or α7 shRNA plasmid DNA as previously described 16 . Briefly, cells were harvested by trypsinization, washed, and resuspended in buffer containing 20 mM Hepes, 137 mM NaCl, 5 mM KCl, 0.7 mM Na 2 HPO 4 , and 6 mM dextrose at pH 7.05. Afterwards, the cells were added to a 0.4-cm-gap cuvette containing the shRNA plasmid DNA, and transfected with a Gene Pulser II electroporation apparatus set at 390v and 500 mF (Bio-Rad, Hercules, CA). Cells were then plated onto 75-mm 2 tissue culture flasks. ShRNA-expressing cells were selected by the addition of 5 µ g/ml puromycin antibiotic for a minimum of 2 weeks. To obtain individual clones, cells were serially diluted into 96-well tissue culture plates. Single colonies were then tested for nAChR levels by Western Blot analysis.
MATERIALS AND METHODS

Reagents and Cell Culture
Western Blot
Western blot analysis was performed on wildtype (WT) LLC cells and cells transfected with control shRNA or shRNAs to α4 and α7 nAChRs as previously described 17 . Protein (40-50 µg) was heated at 90 ºC for 5 minutes and briefly centrifuged. Proteins were transferred onto nitrocellulose membranes using a BioRad Trans-Blot® SD Semi-Dry Transfer Cell machine for 2 hours at 25V.
Blots were incubated overnight in 15mL conicals in 5mL 5% non-fat dry milk in TBST at 4ºC with anti-α4 and/or anti-α7 nAChR (1:500) antibody, washed 3 times for 10 minutes in TBST, and incubated with a secondary anti-rabbit IgG HRP 
Migration Assay
Cells were grown to ~70% confluence in six-well plates in culture media containing DMEM with 10% FBS. A sterile 1000-µl pipette tip was used to create a scratch in 3 separate locations within each well. Media was aspirated and pictures taken at 0 hours to measure the width of the unveiled area. Afterwards, the media (5 mL) was replaced and cells were allowed to recover for 48 hours, after which pictures were taken again to measure the covered area.
Colony Formation Assay
A 0.8% base agar layer was prepared and added to an equal amount of culture media (250 µL/12-/well). Plates were placed at 4ºC for at least 30 minutes to allow base agar layer to gel. Top agar (0.4%) layer was prepared by mixing 0.8% solution with equal amount of culture media (DMEM). Plates were incubated at 37ºC for 5 minutes prior to addition of cells (500/well) followed by incubation for 21 days. Fresh media (500 µl/well) was added every 3-4 days, after aspiration of old media. Afterwards, colonies were photographed and quantified using a Beckman plate reader and cell quantification solution (OD 490 nM). 
Apoptosis Assay
WT LLC cells and control and
Animal Studies
All mice used in this study were obtained from Jackson Laboratories. The institutional animal care and use committee of the University of Louisville approved all experiments. LLC cells were plated out 24 hours prior to injections and were harvested at ~50% confluence to insure cells were in adequate growth phase. LLC cells (5 × 10 5 /100 µl sterile PBS) stably transfected with control non-target shRNA, α4 shRNA, or α7 shRNA were injected subcutaneously into the hind flank of wildtype C57BL/6 mice. Afterwards, tumors were monitored and measured weekly. A tumor size >15mm in any direction was considered the endpoint, according to IACUC regulations. Animals were sacrificed and tissues were harvested for analysis. For experiments using α7 nAChR KO mice, 5 × 10 5 WT LLC cells/100 µl sterile PBS were injected subcutaneously into the hind flank and followed as described above. Animals lacking α7 nAChR and expressing heterozygous mutations for KRAS were developed by breeding mice heterozygous for α7 nAChR with mice heterozygous for KRAS. The double heterozygous progeny were then bred for four generations to develop animals lacking α7 nAChR and expressing heterozygous mutations for KRAS; mutations were confirmed via PCR. These animals developed spontaneous tumors and were sacrificed at 90 days at which time the lungs were harvested for analysis.
Histological Analysis
Animals were euthanized by exposure to carbon dioxide in a closed chamber. Lungs were isolated and inflated at standard pressure, formalin-fixed, paraffin-embedded, and sectioned (6 µm) using a JUNG RM2055 microtome (Leica, Buffalo Groce, IL). They were then transferred onto glass microslides for histological analysis. Sections were deparaffinized, rehydrated, and stained with hematoxylin and eosin (H&E) to evaluate lung tumors. 
Analysis of Data
RESULTS
Nicotine stimulates LLC cell proliferation, but its mitogenic effects are not affected by separate chemical inhibition of α7 or α4 nAChRs
Nicotine has been shown to stimulate lung carcinoma cell proliferation in vitro 18 . To begin to identify key receptors mediating these effects, we exposed WT LLC cells to nicotine and tested the effects of nAChR inhibitors. As presented in Figure 1A -C, nicotine (50µg/mL) stimulated LLC cell proliferation. The mitogenic effects of nicotine were decreased by a broad, non-specific nAChR inhibitor, mecamylamine ( Figure 1A) . However, dihydro-β-erythroidine (DhβE), a more specific inhibitor of α4 nAChRs had little effect ( Figure 1B) . MG624, a more specific inhibitor of α7 nAChRs, also had no affect ( Figure 1C) .
Interestingly, we observed mild increases in proliferation in cells treated with MG624 alone, suggesting a role for α7 nAChR in control of proliferation at baseline in unstimulated cells.
LLC cells silenced for α4 nAChR show decreased migration, colony formation, and apoptosis, while cells silenced for α7 nAChR do not
We transfected WT LLC cells with control shRNA (LLC/Con sh ) or shRNA against α4 nAChR (clones LLC/α4 CLA and LLC/α4 CLB ) or α7 nAChR (clones LLC/α7 CLC and LLC/α7 CLD ). These clones were found to have less than ~75% protein expression for α4 and α7 nAChRs, and these were used for further studies (Figure 2A-2C , respectively). To ensure that the transfection procedure by itself did not affect responsiveness to nicotine, LLC/Con sh cells were exposed to nicotine and treated with DhβE and MG624. Again, nicotine stimulated the proliferation of cells transfected with control shRNA cells and, as before, DhβE and MG624 did not affect the response dramatically (not shown).
We then examined the effect of α4 and α7 nAChR silencing on nicotineinduced LLC proliferation. As presented in Figure 3 , proliferation was again significantly increased in nicotine-treated LLC/UT (untransfected) and LLC/Con sh cells. Consistent with the findings related to the chemical inhibitors, silencing of α4 or α7 nAChRs did not prevent-nicotine-induced proliferation. However, lack of α4 and α7 nAChRs resulted in mild increases in proliferation of unstimulated cells.
We next examined the role of α4 and α7 nAChRs in cellular migration.
Cells were grown to ~80% confluence, after which time, a wound was created using a sterile 1 mL pipette tip. After 48 hours, only ~30% of the initial wound area remained in LLC/UT and LLC/Con sh cells (Figure 4A and 4B) . In contrast, after 48 hours, ~85% and ~75% of the initial wound area remained in the LLC/α4 CLA and LLC/α4 CLB cells, respectively; LLC/α7 CLC and LLC/α7 CLD cells showed no difference compared to controls. (B) WT LLC cells were cultured with increasing concentrations of dhβe in the presence or absence of nicotine (50 µg/mL) for 5 days and treated and processed as described above. Note that dhβe had no effect on nicotine-induced proliferation. (C) WT LLC cells were cultured with increasing concentrations of MG624 in the presence or absence of nicotine (50 µg/mL) for 5 days and treated and processed as described above. MG624 mildly increased baseline proliferation in a dose-dependent manner in untreated cells, and had no effect on nicotine-induced proliferation. All data are depicted as means +/-SD. Asterisks indicate a significant difference from untreated control. Next, we tested the effects of α4 nAChRs on colony formation on soft agar. As depicted in Figure 5A , nicotine significantly increased the number of colonies in LLC/UT and transfected cells. At baseline, overall colony formation was reduced in cells silenced for the α4 nAChR, but the cells remained responsive to nicotine. In contrast, cells silenced for α7 showed no difference in colony number when compared to controls (Figure 5B) .
Lastly, we examined the role of α4 and α7 nAChRs in drug-induced apoptosis. As depicted in Figure 6 , silencing of α4 nAChR significantly reduced the amount of cisplatin-induced apoptosis when compared to LLC/UT cells, as determined by caspase 3/7 activity ( Figure 6A ) and ATP (Figure 6B ) levels, with a greater effect noticed in LLC/α4 CLA cells. Note that α4 nAChR silencing did not affect the number of viable cells. Silencing of α7 nAChRs had no effect.
Mice injected subcutaneously with cancer cells silenced for α4 or α7 nAChR do not display changes in survival compared to controls
Having examined the properties of the α4 and α7 nAChR-silenced clones in vitro, we proceeded to test their role in vivo. To this end, C57BL/6 mice were injected subcutaneously with LLC/Con sh cells, LLC/ α4 sh (clones A and B) cells, or LLC/ α7 sh (clones C and D) cells. Tumor formation and size were followed for up to 12 weeks. 73% of mice injected with LLC/Con sh cells developed tumors over the course of the experiment. In comparison, only 33.3% and 66.7% of the mice injected with LLC/ α4 sh cells (clones A and B, respectively) developed tumors, but this difference was not statistically significant. There was also no difference in tumor size or survival amongst the experimental groups ( Figure   7A,B) . Animals injected with α7 nAChR-silenced clones, also showed no difference in tumor number or size, and did not display changes in survival when compared to those injected with control clones (Figure 7C,D) .
Role of host cell α7 nAChRs in lung cancer
To begin to investigate the role of host cell nAChRs, we injected WT LLC cells into WT C57BL/6 and α7 nAChR knockout mice. As depicted in Figure 8A , animals deficient in α7 nAChRs grew tumors faster compared to wildtype animals, and thus displayed decreased survival between 20 and 30 days (8B).
By their very nature, xenograft models of lung cancer allow for the study of tumor growth and metastasis, but not tumor development. To test this, we chose to study animals with KRAS mutations, which spontaneously develop tumors.
KRAS mutations are relatively frequent in non-small cell lung cancer in humans 19 . Animals with both KRAS mutations and α7 nAChR mutations were sacrificed at 90 days to examine spontaneous tumor development. As presented in Figure 9 , no differences were noted between KRAS and KRAS/α7 nAChR knockout animals with respect to tumor number or size in the lungs. (C,D) LLC/Con sh (n=5), LLC/α7 CLC (n=5) and LLC/α7 CLD (n=4) (5x10 5 ) cells were injected into the hind flank of WT C57BL/6 mice Tumor formation and size were followed up to 12 weeks. A tumor size of ≥15mm in length or width was established as the endpoint according to IACUC regulations. Mice were then sacrificed and lungs harvested and processed for examination of metastases. No differences were noted amongst groups when evaluating tumor size (C) and survival (D). 
DISCUSSION
It is well established that tobacco use is the number one risk factor for development of lung cancer, which will take the lives of millions of people worldwide this year 4 . Despite major increases in survival rates of many cancers, little progress has been made in the treatment of lung cancer. Data, however, are emerging showing important roles for nAChRs in cancer biology, which places emphasis on the role of nicotine, an important component of tobacco and an exogenous ligand for these receptors 20 . The mitogenic effects of nicotine are well known and a number of investigators have shown that these effects can be abolished by using chemical nAChR antagonists, such as α-bungarotoxin [21] [22] [23] .
However, results obtained from experiments using such antagonists must be viewed with caution due to off-target effects. An important example is varenicline, a prescription drug used for smoking cessation. The mechanism of action of varenicline is reported to be through partial agonism of α4β2 nAChRs receptors 24 , but recent data suggest that this agent also binds to α3-and α6containing nAChRs and displays full agonism on α7 nAChRs 25 . These off-target effects make it difficult to examine the role of individual nAChRs when using such chemicals. We thus used shRNA technology to knockdown a single, specific nAChR subunit at a time, allowing for careful delineation of the roles of the different receptors. We tested LLCs because of the extensive literature available using these cells to study lung cancer in models that allow their use in normal, immunocompetant C57BL/6 mice.
First, we confirmed that nicotine exerted mitogenic effects on WT LLC cells. Note that, as previously reported 18 , this effect was relatively small (~30-40%), which is likely due to the fact that the cells were not starved prior to stimulation as others have reported 11, 26 . At least one group has shown that the ability of nicotine to increase expression of Akt, Erk, and mTOR activation in vitro, was largely dependent on the absence of serum which causes lower basal levels of pathway activation 27 . Instead, the cells were cultured in 2% fetal bovine serum, which we believe is more physiologically relevant. Although the most robust effect was noted at the highest dose tested (276% increase over control), we chose to use doses more physiologically relevant for further experiments. As expected, based on the literature, we found that a non-specific nAChR chemical inhibitor (e.g., mecamylamine) diminished nicotine-induced LLC cell proliferation, although the effect was relatively small. However, more specific inhibitors targeting α4 or α7 nAChRs independently did not inhibit nicotine-induced cell proliferation, while the α7 nAChR antagonist had a small mitogenic effect at higher doses. This lack of a significant inhibitory activity was confirmed in cells silenced specifically for either the α4 or the α7 nAChR subunits. This may suggest that nAChRs containing the α4 and α7 subunits play little role in nicotine-induced proliferation, and that effects seen in other studies performed using chemical antagonists were indeed due to off-target effects. On the other hand, we believe it is more likely that nicotine-induced proliferation in LLC cells is not mediated by a single nAChR, but several, and that blocking one or the other independently is not sufficient to completely inhibit proliferation. In other words, both α4 and α7 nAChRs, and perhaps others, need to be targeted to inhibit nicotine-induced cell proliferation. One interesting observation that remains unexplained relates to the mild induction of proliferation observed in unstimulated α7 nAChR-silenced cells. We have observed a similar effect in lung fibroblasts (unpublished data); this seemingly paradoxical effect has been reported in the literature in airway epithelial basal cells 28 . Our data suggest that α7 nAChRs might restrain proliferation in unstimulated cells, while this effect is overcome in cells lacking this receptor. This raises the possibility of multiple receptors mediating these effects, but this requires further investigation.
In contrast to our observations regarding cell proliferation, we found that cells silenced for α4 nAChRs, but not α7 nAChRs, showed reduced migration and ability to form colonies on soft agar when compared to controls. Deficiency of α4 nAChRs also resulted in resistance to cisplatin-induced apoptosis.
Having characterized the clones in vitro, we turned our attention to testing the roles of these receptors in an in vivo model of lung cancer. For this, cells silenced for α4 or α7 nAChR subunits were injected subcutaneously into C57BL/6 mice. Mice injected with cells silenced for α4 nAChRs developed fewer tumors, but this was not statistically significant. No differences were observed in animals injected with control or α7 nAChR deficient cells. Tumor size was also not different between groups. Importantly, silencing α4 or α7 nAChRs independently had no significant effect on the survival of animals. Note that tumor growth and progression (and animal survival) were tested in untreated animals suggesting that these nAChRs play insignificant roles in tumor progression in the absence of exogenous stimulation. Whether these receptors play roles in tumor progression in the setting of nicotine exposure awaits further exploration.
Finally, we turned our attention to host cell nAChRs. We focused on α7 nAChRs because of the availability of C57BL/6 mice with α7 nAChR knockout mutations 29 . In the xenograft model, we found increased tumor progression in α7 nAChR knockout animals, which is consistent with our in vitro proliferation data for α7 nAChR silencing in unstimulated cells. However, when we created animals with double mutations in KRAS and α7 nAChRs to test spontaneous tumor development, the number and size of lung tumors was similar to that in KRAS mice with wildtype expression of α7 nAChRs. Together, these studies suggest that host cell α7 nAChRs may not play critical roles in tumor development driven by mutations, but may play a vital role in cancers driven by oncogenic microenvironments.
Another explanation is that other nAChRs overcompensate when α7 nAChRs are absent. As stated before, in cultured tumor cells (this report) and in lung fibroblasts (unpublished observations), absence of α7 nAChRs leads to increased cellular proliferation.
In summary, our studies shed light into the differential roles that α4 and α7 nAChRs play in LLC cells when tested in vitro. Specifically, α4 nAChRs were found to promote lung carcinoma cell migration and colony formation on soft agar. α4 nAChRs were also found to play a role in cisplatin-induced apoptosis.
α7 nAChRs appear to have little to no effect on these processes, but both receptors seem to play roles in cellular proliferation at baseline in unstimulated cells. However, studies in animals suggest that neither receptor in the tumor cell is essential for tumor development, growth, and progression in vivo in the absence of exogenous nicotine stimulation. Rather, our in vivo studies point to an important role of these receptors, specifically the α7 nAChRs, in the host.
Together, our studies suggest that targeting one receptor alone might be insufficient to inhibit tumor progression in vivo, while targeting multiple nAChRs might prove more successful. Further exploration of the differential roles of nAChRs in both cancer cells and host cells, especially in humans, will undoubtedly enhance our understanding of how they influence cancer and other biological processes. This work is expected to better direct our efforts towards the development of effective strategies for intervention in the setting of lung cancer and other tumors.
SUMMARY AND CONCLUSIONS
CAVEATS AND WEAKNESSES
Our main goal in this study was to determine if nAChRs played an important role in the development and progression of lung cancer. Previous studies implicating these receptors in the etiology of lung cancer utilized chemical antagonists in their methodology, which are notorious for their off-target effects. While we believe our approach using shRNA technology is more specific and targeted to individual receptors, it is important to note that knocking down the expression of one receptor could lead to a compensatory increase or decrease in the expression of other nAChRs and/or other relevant molecules.
While our data suggest the α4 and α7 nAChRs may play little to no role, individually, in lung cancer progression, our data utilizing knockout animals suggest an important role of the α7 nAChR in the host. We are now in the process of developing an α4 nAChR knockout animal to further study the role of these receptors in the host. However, this study did not offer any insight into what cells and mechanisms might be mediating these effects. A vast number of cell types in the body express nAChRs, and so knockout animals could have a large number of processes affected compared to wildtype animals. Additional studies are needed to examine exactly what is causing these effects in the α7 nAChR deficient animals.
FUTURE WORK
The future directions described here will seek to address the questions that remain unanswered, as well as new questions that have arisen, in our attempts to better understand the role that nAChRs play in lung cancer development and progression. Our data presented here suggest an important role for the host in lung cancer progression. For our future studies, we thus chose to examine three aspects of the host that we believe important in helping us better understand lung cancer development and progression.
Role of host nAChRs
Amidst the perceived importance of host nAChRs in the etiology of lung cancer, we hypothesize that activation of nAChRs in lung fibroblasts promotes an oncogenic microenvironment that renders the host susceptible to lung cancer development and progression. We will examine this by exposing animals chronically with nicotine in their drinking water and then injecting them with LLC cells and examining tumor development and metastases. Presumably, any differences we observe will be through affects on the host. However, signaling through nAChRs has been shown to affect a number of different host responses, such as inflammation, alterations in the immune system, and angiogenesis. We will also examine these processes and investigate what cells and mechanisms are mediating these effects.
Role of tumor cell-stromal interactions
Recent studies have implicated the tumor microenvironment as a new chemotherapeutic target, by demonstrating the importance of tumor cell-stromal interactions in tumor progression. However, the exact mechanisms of how tumor cell-stromal interactions drive lung cancer progression remain undefined. We suspect host fibroblasts represent an important component of the tumor microenvironment that may help drive tumor progression. Consistent with the latter, we found that human NSCLC cells show alterations in cell morphology, increased proliferation, and increased colony formation on soft agar when exposed to conditioned media harvested from IMR-90 lung fibroblasts.
Interestingly, the fibroblast-derived conditioned media also promoted tumor cell resistance to cisplatin-induced apoptosis. We plan on investigating these interactions further, performing in vivo studies, and determining exactly what soluble factors are mediating these responses.
Role of aging in the etiology lung cancer
Cancer incidence is known to rise exponentially with age. This is thought to be due to the accumulation of oncogenic mutations, as well as changes in the tissue microenvironment. Consistent with this, we found that aged animals showed greater metastases to the lung in our LLC model when compared to young animals (Figures 10-12) . We began to inquire into the mechanisms for this observation. Dean Jones at Emory University, after testing hundreds of healthy and diseased individuals, has recently shown that the physiological cysteine/cystine redox potential found in the plasma of healthy subjects is around -80 mV. In subjects with disease, this redox potential may be oxidized to values between -62 to -20 mV. Relevant to our proposal is the fact that aging is associated with alterations in this mechanism. We have shown that this oxidative stress can activate nAChRs, and lead to increased expression of extracellular matrix proteins. We have also shown that aged lungs show alterations in the expression of extracellular matrices. We thus hypothesize that aging, by activation of nAChRs in the lung via oxidation of the cysteine/cystine redox potential, promotes an oncogenic microenvironment that renders the host susceptible to lung cancer development and progression. If this is true, we deduce that we can prevent lung metastasis in old animals through dietary interventions. Cysteine and cystine are derived from dietary sulfur amino acids and Dean Jones has also shown that oxidation of the cysteine/cystine redox potential could be mimicked in rodents exposed to a diet with low sulfur content, while a diet with high sulfur content could reverse the effect 30 . Thus, we predict that a diet with supplementation of sulfur can reverse the oncogenic microenvironment observed in aged animals. . Old animals are more susceptible to lung cancer metastasis Young (4 months, n=7) and old (19 months, n=7) WT C57BL/6 animals were injected with 1x10 6 WT LLC cells into the hind flank. Tumor formation and size were followed up to 2 weeks. A tumor size of ≥15mm in length or width was established as the endpoint according to IACUC regulations. Mice were sacrificed at 2 weeks and lungs harvested and processed for examination of metastases. All animals developed tumors at the site of injection, with no differences in size observed. 1/7 animals in the young group developed metastases, while 6/7 animals in the old group developed metastases.
Figure 12
Figure 12. Lung images of young versus old mice injected with LLC cells
Young (4 months, n=7) and old (19 months, n=7) WT C57BL/6 animals were injected with 1x10 6 WT LLC cells into the hind flank. Tumor formation and size were followed up to 2 weeks. A tumor size of ≥15mm in length or width was established as the endpoint according to IACUC regulations. Mice were sacrificed at 2 weeks and lungs harvested and processed for examination of metastases.
